Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress
A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more
Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more
The leading vaccine innovator has won plaudits for its commitment not to enforce its coronavirus-related IP rights against other mRNA inventors Read more
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more
Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more
With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more
Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more
The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets Read more
The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets Read more
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more
The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets Read more
@IAM_Alerts RT @IAM_Alerts: @cstorm15 The danger is not so much that decisions are taken out of the patent bubble, but that decisions are made without… Read more
11May2021
@IAM_Alerts RT @uspto: Today, the #USPTO officially issued U.S. patent number 11 million, a significant milestone in the history of American innovation… Read more
